Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

E-ISSN： 1873-5576|10|4|392-401

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.4, 2010-06, pp. : 392-401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate Keam Susan J.

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?

Current Cancer Drug Targets, Vol. 10, Iss. 8, 2010-12 ,pp. : 834-839

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry

By Berry William R.

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2295-2297

Adis International

Access to resources Recommend Favorite

Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer

By Eton David T. Shevrin Daniel H. Beaumont Jennifer Victorson David Cella David

Value in Health, Vol. 13, Iss. 5, 2010-08 ,pp. : 613-623

Blackwell Publishing

Access to resources Recommend Favorite

Anti-Tumor Effect of AlkB Homolog 3 Knockdown in Hormone- Independent Prostate Cancer Cells

Current Cancer Drug Targets, Vol. 12, Iss. 7, 2012-09 ,pp. : 847-856

Bentham Science Publishers

Access to resources Recommend Favorite